EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 744 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... April 24, 2019 Five Questions With…Desiree. April 21, 2022 Getting Help for Sexual Health Problems When You Have Head and... April 14, 2022 GreaterGood Charities Provides Supplies and Support to People and Pets After... December 17, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Ribociclib to Include Use in... Improving cancer care for the LGBTQ+ community What to Know About Cancer Care and Research for People 65+:... Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response
